Sirolimus
Small molecule targets CXCR4, IL2, MTOR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 8 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | RAPAMUNE | — | 2003-04-11 – 2015-05-28 | fda.gov ↗ |
| Approved | EU (EMA) | Rapamune | — | 2001-03-13 | europa.eu ↗ |
| Approved | US (FDA) | RAPAMUNE | — | 1999-09-15 | fda.gov ↗ |
Trials 478 · started per year
Also used as a comparator or background therapy in 216 trials
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-05-29 | Pfizer | Pfizer’s RAPAMUNE® (sirolimus) Becomes First FDA-Approved Treatment for Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease pfizer.com ↗ |
| 2015-02-20 | Pfizer | FDA Accepts Supplemental New Drug Application for Priority Review of RAPAMUNE® (sirolimus) for Treatment of Lymphangioleiomyomatosis (LAM) pfizer.com ↗ |
| 2011-08-03 | Pfizer | Biotica regains worldwide rights to its rapamycin analogue program pfizer.com ↗ |
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 718 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sirolimus | “The development of LAM-001 for lung transplant related BOS, conceptually a T-cell driven process against transplanted alloantigen, is based on the principal hypothesis that...” NCT06018766 ↗579“The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin...” NCT02913261 ↗ “The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗ “Patients will receive the recommended phase 2 dose (RP2D) of SM-88 (460 mg by mouth [PO] twice a day [BID] D1 - 28) as well as three conditioning agents (MPS): methoxsalen (10...” NCT04720664 ↗ “High-dose, post-transplantation cyclophosphamide (PTCy) 25-50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +90, and mycophenolate mofetil (MMF) on days +5 through...” NCT02579967 ↗ “The trial evaluates the safety and efficacy of the Magic Touch PTA sirolimus drug-coated balloon in comparison to the treatment with PTX drug-coated balloon (control device) in...” NCT04475783 ↗ “Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of...” NCT04177095 ↗ “The purpose of this study is to evaluate the side effects of sirolimus (rapamycin) given in combination with chemotherapy (Mitoxantrone + Etoposide + Cytarabine (MEC)) on high...” NCT00780104 ↗ “LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the...” NCT03711929 ↗ “Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter” NCT00679042 ↗ “The PK sub-study is being conducted to assess the blood pharmacokinetics of the three drugs (Sirolimus, Rivaroxaban, Argatroban) eluted from the DESyne BDS Plus after implantation.” NCT05033964 ↗ “Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants.” NCT01889992 ↗ “The biodegradable polymer sirolimus eluting Combo stent is a dual-therapy sirolimus-eluting and CD34+ antibody coated stent capturing endothelial progenitor cells (EPCs).” PMID 39870125 ↗ Jan 2025 “Sirolimus gel, 0.2%, demonstrated a significant clinical benefit for patients with TSC involving angiofibromas, thus providing a promising therapeutic modality.” PMID 29800026 ↗ Jul 2018 “Rapamycin (sirolimus) is a drug that targets the mTOR (mammalian target of rapamycin) protein involved in the PI3K-Akt signalling pathway downstream of PI3K.” NCT06308445 ↗ “Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml” NCT00520130 ↗ “This new formulation, encapsulated rapamycin (sirolimus), provides a more predictable bioavailability of this drug than \[the other formulation\].” NCT03618355 ↗ “Sirolimus at least 7-10 days prior to receiving the first dose of cemiplimab (Cycle 1, Day 1) and then daily while receiving Cemiplimab” NCT04339062 ↗ “A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation.” NCT00195481 ↗ “Racemetyrosine (SM-88) is an amino-acid analogue used with methoxsalen, phenytoin, and sirolimus (MPS) to enhance SM-88 activity.” PMID 32924093 ↗ Sep 2020 “ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus.” NCT02009332 ↗ “Assigned Interventions Sirolimus (Rapamune) Tacrolimus (Prograft) Prednisone (Deltasone, Prednicot, Rayos, Sterapred)” NCT04415476 ↗ “Sirolimus orally, monitored two times a week to maintain a target therapeutic plasma level of 8-15 ng/ml from day +5.” NCT03434704 ↗ “Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year” NCT02165007 ↗ “Subject will be randomized to take Sirolimus (Rapamycin) 0.5mg once daily for 2 years or until disease recurrence” NCT03298958 ↗ “Sodium valproate extended-release tablets 0.5g/day; sirolimus tablets 1mg/day and calcitriol capsules 0.25μg/day.” NCT05920512 ↗ “such as Etanercept and infliximab, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis” NCT02694770 ↗ “take oral Sirolimus (1 mg/m2/day) for 7 days (from 3 days before UCB infusion until 3 days after UCB infusion)” NCT03871972 ↗ “Sirolimus: Start at 5 mg/day as soon as treatment allocation arrives to obtain targeting levels to 8 -15 ng/ml” NCT01195194 ↗ “Immunosuppressive regimen consisting of calcineurin inhibitor, mycophenolate mofetil, sirolimus or ivermus” NCT04168944 ↗ “Subjects will receive either Hydroxychloroquine with Azithromycin or Hydroxychloroquine with Sirolimus” NCT04374903 ↗ “Evaluate the tolerability and efficacy of sirolimus (rapamycin) in combination with low-dose aracytin” NCT00235560 ↗ “test two of these drugs, Rapamycin (Sirolimus) and Everolimus (Afinitor), in healthy older adults” NCT06658093 ↗ “Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD)” NCT01582048 ↗ “the combination of the drugs daclizumab and sirolimus can effectively treat adults with uveitis” NCT00078689 ↗ “Study Evaluating Sirolimus in End Stage Renal Disease in High Risk Kidney Transplant Recipients” NCT00044720 ↗ “Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.” NCT01280669 ↗ “The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.” NCT02166177 ↗ “Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer” NCT00352950 ↗ “Sirolimus: 12 mg PO on days -3 to 60, followed by a taper if GVHD does not develop.” NCT02356159 ↗ “• A mammalian target of rapamycin (mTOR) inhibitor (everolimus or sirolimus)” NCT06821542 ↗ “• A mammalian target of rapamycin (mTOR) inhibitor (everolimus or sirolimus)” NCT07124078 ↗ “Sirolimus (rapamycin, Rapamune , RAPA) is a novel immunosuppressive agent” NCT00061360 ↗ “an immunotherapy called SEL-110, a nano-encapsulated form of sirolimus.” NCT05778877 ↗ “The study allowed SOC regimen is tacrolimus + sirolimus or everolimus.” NCT06552169 ↗ “Sirolimus 8mg-12mg oral loading dose followed by single dose 4mg/day.” NCT02991898 ↗ “Sirolimus is an inhibitor of the mammalian target of rapamycin (mTOR)” NCT02776202 ↗ “mTOR inhibitors (everolimus or sirolimus), vedolizumab, ruxolitinib.” NCT05132166 ↗ “Participants will receive sirolimus orally (3 mg/day) for 6 months.” NCT02554955 ↗ “Rapamycin (Sirolimus) Treatment for Amyotrophic Lateral Sclerosis” NCT03359538 ↗ “mycophenolate mofetil (MMF) and tacrolimus converted to sirolimus” NCT00619528 ↗ “Sirolimus: Starting dose 1 mg/d, orally, once a day.” NCT07518277 ↗ “Rapamune® (sirolimus) 2 mg tablet for oral dosing.” NCT03972462 ↗ “sirolimus po trough levels 10-15 ng/ml X 3 months” NCT00566813 ↗ “Sirolimus may be substituted for tacrolimus.” NCT05298358 ↗ “NPC-12G gel is containing 0.2% Sirolimus” NCT04461886 ↗ “NPC-12Y gel is containing 0.2% Sirolimus” NCT05495425 ↗ “NPC-12G gel is containing 0.2% Sirolimus” NCT02634931 ↗ “Sirolimus, MMF, Mycophenolate Mofetil” NCT01062555 ↗ “PTX-022 (Sirolimus) Topical Gel 3.9%” NCT06653842 ↗ “Sirolimus 3.9% Topical Gel (PTX-022)” NCT05050149 ↗ “PTX-022 (Sirolimus) Topical Gel 3.9%” NCT07552077 ↗ “QTORIN 3.9 % Sirolimus Topical Gel” NCT04893486 ↗ “advagrf+sirolimus one time to eat.” NCT01964014 ↗ “plus 1 mg of sirolimus/rapamycin” NCT01031901 ↗ “Sirolimus on days +5 through +60” NCT03922724 ↗ “Rapamune, sirolimus, rapamycin” NCT01843998 ↗ “prednisone + sirolimus” NCT06981845 ↗ “Rapamycin (sirolimus)” NCT00375245 ↗ “Sirolimus (Rapamune®)” NCT01680952 ↗ “Sirolimus (Rapamune)” NCT00252655 ↗ “rapamune (Sirolimus)” NCT01005706 ↗ “Sirolimus, RAPA” NCT04629495 ↗ “Sirolimus” NCT02165007 ↗ “Sirolimus” NCT01889992 ↗ |
| Known as | (RAPA, RapamuneR) (sirolimus) | “(RAPA, RapamuneR) (sirolimus)” NCT00795886 ↗ |
| Known as | ABI-009 | “ABI-009 is a nanoparticle albumin-bound (nab®) formulation of the mammalian Target of Rapamycin ( mTOR) inhibitor, sirolimus.” NCT02009332 ↗ |
| Known as | DE-109 | “LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the...” NCT03711929 ↗ |
| Known as | Encapsulated Rapamycin | “The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).” NCT03618355 ↗1“Encapsulated Rapamycin (eRapa)” NCT04230499 ↗ |
| Known as | eRapa | “The eRapa (encapsulated rapamycin) drug product consists of sub-micron rapamycin particles incorporated into poly(methyl methacrylate) polymer (Eudragit® L 100 / S 100).” NCT03618355 ↗1“0.5mg eRapa (encapsulated rapamycin) oral capsules” NCT04375813 ↗ |
| Known as | MS-R001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00401115 ↗ |
| Known as | MS-R001, rapamycin | “MS-R001, rapamycin” NCT00656643 ↗ |
| Known as | MS-R002, rapamycin | “MS-R002, rapamycin” NCT00656643 ↗ |
| Known as | MS-R003, rapamycin | “MS-R003, rapamycin” NCT00656643 ↗ |
| Known as | NPC-12G | “The purpose of this trial is to evaluate the safety and efficacy of long-term treatment with NPC-12G gel (0.2% sirolimus gel) to angiofibroma and other skin lesions in patients...” NCT02634931 ↗1“NPC-12G gel (topical formulation of sirolimus)” NCT02635789 ↗ |
| Known as | PTX-022 | “The purpose of this OLT study is to investigate the safety of long term exposure and pharmacokinetics (PK) of QTORIN rapamycin 3.9% anhydrous gel or "PTX-022".” NCT05643872 ↗4“This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita.” NCT03920228 ↗ “This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations.” NCT05050149 ↗ “PTX-022 (Sirolimus) Topical Gel 3.9%” NCT06653842 ↗ “PTX-022 (Sirolimus) Topical Gel 3.9%” NCT07552077 ↗ |
| Known as | QTORIN | “A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of...” NCT05180708 ↗1“QTORIN 3.9% Rapamycin Anhydrous Gel” NCT06239480 ↗ |
| Known as | QTORIN Sirolimus | “Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations” NCT05050149 ↗ |
| Known as | Rap | “the mTOR inhibitor sirolimus (Rap) found that administering the drug” NCT06719791 ↗ |
| Known as | RAPA | “Evaluation of central nervous system penetration of orally administered Rapamune (RAPA) in older adults with Mild Cognitive Impairment (MCI) or early Alzheimer's disease (AD)...” NCT04200911 ↗7“Inhibition of the mTOR pathway by rapamycin (RAPA), an immunosuppressive drug used as adjunct therapy in preventing solid organ allograft rejection, enhances longevity in mice.” NCT02874924 ↗ “the autophagy inhibitor: hydroxychloroquine (HCQ) and the autophagy inducer: sirolimus (rapamycin, Rapa) would reduce glucose utilization in sarcoma patients.” PMID 26375670 ↗ Oct 2015 “rapamycin (RAPA), a key component of the immunosuppressive regimen in clinical islet transplantation” PMID 21084848 ↗ Jul 2009 “daily 0.5-1.0 ml applications of 8% RAPA (Rapamycin) in a petrolatum vehicle” NCT04049552 ↗ “Sirolimus (rapamycin, Rapamune , RAPA) is a novel immunosuppressive agent” NCT00061360 ↗ “Rapamycin (RAPA)” NCT00803010 ↗ “Sirolimus, RAPA” NCT04629495 ↗ |
| Known as | rapamun | “Sirolimus (rapamun) is an mTOR inhibitor” NCT05549167 ↗ |
| Known as | Rapamune | “Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation...” NCT00993499 ↗41“At 1 month, they will have a kidney biopsy and if it is ok, patients will be treated long term with either continued tacrolimus/mycophenolate mofetil or be switched to...” NCT00170053 ↗ “Study to Compare the Safety and Efficacy of Sirolimus (Rapamune) to Tacrolimus (Advagraf) Associated to Mycophenolate Mofetil (CellCept) Between 12 and 36 Months After Kidney...” NCT00811915 ↗ “In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).” NCT02062892 ↗ “A Post Marketing Surveillance Looking at Safety of Rapamune (Sirolimus) in Indian Population Undergoing de Novo Renal Transplantation.” NCT00195481 ↗ “Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy” NCT02979873 ↗ “A Phase I/II, Open-Label Pilot Trial to Evaluate the Safety of Rapamune (Sirolimus) in Patients With Multiple Sclerosis” NCT00095329 ↗ “These newer medications include Prograf (tacrolimus), Cellcept (mycophenolate mofetil), and Rapamune (sirolimus).” NCT00352092 ↗ “A Phase I/II Trial of Sirolimus (Rapamune) and Cyclosporine in Patients With Refractory Aplastic Anemia” NCT00319878 ↗ “Sirolimus (rapamycin, Rapamune , RAPA) is a novel immunosuppressive agent” NCT00061360 ↗ “Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.” NCT01620307 ↗ “Mycophenolate Mofetil; MMF (CellCept) and Sirolimus (Rapamune)” NCT00374647 ↗ “Sirolimus (RAPAMUNE) drug-coated balloon angioplasty catheter” NCT07359807 ↗ “CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)” NCT00789308 ↗ “Rapamune® (sirolimus) 2 mg tablet for oral dosing.” NCT03972462 ↗ “induction therapy with CsA and Rapamune” NCT00195468 ↗ “Sirolimus (rapamycin, Rapamune)” NCT00743509 ↗ “Rapamune, sirolimus, rapamycin” NCT01843998 ↗ “Rapamune (sirolimus/rapamycin)” NCT00896012 ↗ “TOPICAL SIROLIMUS (RAPAMUNE*)” NCT01061853 ↗ “Drug: Rapamune (Sirolimus)” NCT00167947 ↗ “Sirolimus (Rapamune®)” NCT07378657 ↗ “Rapamune® (Sirolimus)” NCT00518271 ↗ “Rapamune® (rapamycin)” NCT02505893 ↗ “Sirolimus (Rapamune®)” NCT01680952 ↗ “Rapamune® (Sirolimus)” NCT00518375 ↗ “Sirolimus (Rapamune®)” NCT00478608 ↗ “Rapamune® (Sirolimus)” NCT00519116 ↗ “Sirolimus (Rapamune®)” NCT07662174 ↗ “Sirolimus (Rapamune)” NCT00252655 ↗ “Sirolimus (RAPAMUNE)” NCT07656909 ↗ “Sirolimus (RAPAMUNE)” NCT07587801 ↗ “Sirolimus (Rapamune)” NCT00086346 ↗ “Sirolimus (RAPAMUNE)” NCT00037531 ↗ |
| Known as | rapamune (Sirolimus) | “rapamune (Sirolimus)” NCT01005706 ↗ |
| Known as | Rapamune (sirolimus, rapamycin) | “Rapamune (sirolimus, rapamycin)” NCT01488253 ↗ |
| Known as | Rapamune [Registered Trademark] | “This study will determine the safety and effectiveness of sirolimus (Rapamune® (Registered Trademark)) in treating focal segmental glomerulosclerosis (FSGS), a disease...” NCT00040508 ↗1“A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC” NCT00923273 ↗ |
| Known as | rapamycin | “PURPOSE: Pharmacodynamic studies are frequently incorporated into phase I trials, but it is uncommon that they guide dose selection. We conducted a dose selection study with...” PMID 18757332 ↗ Sep 2008155“BACKGROUND: Perturbation of the mechanistic target of rapamycin (mTOR) pathway can instruct effector versus memory cell fate of tumor antigen-specific T cells in preclinical...” PMID 40132910 ↗ Mar 2025 “The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation compared to Placebo on the signs and symptoms of dry eye in the...” NCT00814944 ↗ “Sirolimus, also known as rapamycin, is a macrolide compound that inhibits its mechanistic target (mTOR), which regulates cell growth and metabolism in response to environmental cues.” NCT05746689 ↗ “A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC” NCT00923273 ↗ “Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants.” NCT01889992 ↗ “Sirolimus, also known as rapamycin, is a lipophilic macrolide isolated from a strain of Streptomyces hygroscopicus that serves as a strong HbF inducer in vitro and in vivo.” PMID 35755297 ↗ Jun 2022 “Sirolimus, also known as rapamycin, is an immunosuppressant that is used to prevent organ transplant rejection by inhibiting mammalian target of rapamycin (mTOR) kinase.” NCT04461340 ↗ “The purpose of this OLT study is to investigate the safety of long term exposure and pharmacokinetics (PK) of QTORIN rapamycin 3.9% anhydrous gel or "PTX-022".” NCT05643872 ↗ “the autophagy inhibitor: hydroxychloroquine (HCQ) and the autophagy inducer: sirolimus (rapamycin, Rapa) would reduce glucose utilization in sarcoma patients.” PMID 26375670 ↗ Oct 2015 “Rapamycin or sirolimus is an anti-inflammatory and immunomodulatory drug that has an enormous potential in ocular surface pathologies such as dry eye disease.” NCT04115800 ↗ “This study evaluates the safety and efficacy of PTX-022, topical rapamycin, in the treatment of adults with moderate to severe Pachyonychia Congenita.” NCT03920228 ↗ “We examined the effect of the mTOR inhibitor sirolimus (rapamycin) on renal functional loss and cyst progression in the Han:SPRD rat model of ADPKD.” PMID 16221708 ↗ Oct 2005 “This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst), an oral immunosuppressant agent recently approved by the FDA.” NCT00006178 ↗ “Sirolimus (rapamycin) is an mTOR inhibitor that promotes α-synuclein autophagy and reduces its associated neurotoxicity in preclinical models.” PMID 35040506 ↗ Jan 2022 “The purpose of this research is to see if the drug rapamycin will improve the heart's ability to pump by improving your oxygen consumption.” NCT04996719 ↗ “Sirolimus (rapamycin) is an agent produced by the bacterium Streptomyces hygroscopicus, inhibits the mammalian target of rapamycin (mTOR).” NCT03364764 ↗ “Sirolimus (rapamycin) is an agent produced by the bacterium Streptomyces hygroscopicus, inhibits the mammalian target of rapamycin (mTOR).” NCT04470804 ↗ “Rapamycin (as Sirolimus) is an immunosuppressant agent, approved by the FDA for acute rejection prevention in renal transplant recipients.” NCT04247750 ↗ “Treatment of port wine stains using Pulsed Dye Laser, Erbium YAG Laser, and topical rapamycin (sirolimus)-A randomized controlled trial.” PMID 27320685 ↗ Jun 2016 “Phase II Clinical, Biological and Pharmacological Study of Rapamycin (Rapamune®, Sirolimus) in Patients With Advanced Pancreatic Cancer” NCT00499486 ↗ “Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine.” PMID 10221490 ↗ Apr 1999 “Sirolimus (rapamycin), produced by the bacterium Streptomyces hygroscopicus, is a mammalian target of Rapamycin (mTOR) inhibitor.” NCT03866681 ↗ “This will be combined with sirolimus (rapamycin, Wyeth-Ayerst), an oral immunosuppressant agent recently approved by the FDA.” NCT00062712 ↗ “The experimental group received rapamycin 2 mg/day orally for 24 weeks on the basis of methylprednisolone pulse therapy” NCT05532072 ↗ “Sirolimus, also known as rapamycin, is currently the only FDA-approved mammalian target of rapamycin (mTOR) inhibitor.” NCT03987152 ↗ “Rapamycin or sirolimus is a macrocyclic immunosuppressive drug that inhibits the mammalian target of rapamycin (mTOR).” NCT05237687 ↗ “Sirolimus (formerly known as Rapamycin) is a drug commonly used after renal transplants to prevent organ rejection.” NCT01313923 ↗ “Sirolimus (Rapamycin) is an immunosuppressant mostly used for the management of kidney transplant recipients.” NCT00491517 ↗ “Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30.” NCT00317798 ↗ “A PHASE I/II STUDY OF RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH METHOTREXATE (MTX) AND CYCLOSPORINE (CPS)” NCT00002790 ↗ “Pre-clinical data suggests that dMMR tumors are susceptible to rapamycin (sirolimus), an mTOR inhibitor.” NCT04393454 ↗ “Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle.” NCT01135563 ↗ “Infusion with SC-DARIC33 followed by intermittent oral rapamycin administration” NCT05105152 ↗ “Rapamycin (sirolimus) treatment suppresses mTORC1 but also induces autophagy” PMID 31299246 ↗ Jul 2019 “Sirolimus (rapamycin, Rapamune , RAPA) is a novel immunosuppressive agent” NCT00061360 ↗ “Oral rapamycin is given as a monotherapy at a initial dose of 0.8mg/m2” NCT04598204 ↗ “pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days” NCT01346085 ↗ “Sirolimus (Rapamycin) for Slow-Flow Malformations in Children:” PMID 34524406 ↗ Nov 2021 “Rapamycin p.o.: 4 mg/d, (target 8-15 ng/ml) (starting day -7)” NCT03963024 ↗ “subjects will take a once weekly 6 mg dose of rapamycin” NCT04994561 ↗ “0.5mg eRapa (encapsulated rapamycin) oral capsules” NCT04375813 ↗ “sirolimus (rapamycin; Th2.rapa cells)” NCT00923845 ↗ “Pralatrexate Rapamycin Regorafenib” NCT02551718 ↗ “Sirolimus (rapamycin, Rapamune)” NCT00743509 ↗ “Rapamune, sirolimus, rapamycin” NCT01843998 ↗ “Rapamune (sirolimus/rapamycin)” NCT00896012 ↗ “Sirolimus (Rapamycin)” NCT01054313 ↗ “Sirolimus (rapamycin)” NCT00993499 ↗ “Rapamycin, sirolimus” NCT00457808 ↗ “MS-R001 (rapamycin)” NCT00401115 ↗ “rapamycin” NCT01536054 ↗ |
| Known as | SEL-110 | “an immunotherapy called SEL-110, a nano-encapsulated form of sirolimus.” NCT05778877 ↗ |
| Known as | SIR | “Because sirolimus (SIR) monotherapy was successful in kidney transplantation under antithymocyte globulin (ATG), we undertook a pilot study comparing SIR monotherapy with...” PMID 18212631 ↗ Jan 20083“Sirolimus (SIR) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice.” NCT02891603 ↗ “comparing sirolimus (SIR) with azathioprine (AZA) in a tacrolimus-based immunosuppressive regimen in lung transplantation.” PMID 20833822 ↗ Sep 2010 “rapamycin (mTOR) inhibitor sirolimus (SIR) is an immunosuppressant” PMID 25899445 ↗ Apr 2015 |
| Known as | Siro | “BACKGROUND: In an attempt to reduce chronic calcineurin inhibitor induced allograft nephropathy in first cadaver and human leukocyte antigen non-identical living-donor renal...” PMID 14742990 ↗ Jan 2004 |
| Known as | Sirolimus (albumin - bound) | “Sirolimus (albumin - bound): Dose escalation, intravenous infusion” NCT06856200 ↗ |
| Known as | Sirolimus (Rapamycin) | “Sirolimus (Rapamycin)” NCT01709136 ↗ |
| Known as | sirolimus - Rapamune | “Sirolimus (Rapamune®)” NCT00679042 ↗1“sirolimus - Rapamune” NCT00672243 ↗ |
| Known as | Sirolimus for Injection (Albumin Bound) | “Sirolimus for Injection (Albumin Bound), intravenously, once a week, 28 days per cycle (three weeks-on and one week-off)” NCT05125523 ↗ |
| Known as | Sirolimus+MMF or MPS or AZA+Steroid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00452361 ↗ |
| Known as | SRL | “As conversion from calcineurin inhibitor to sirolimus (SRL), a mechanistic target of rapamycin inhibitor (mTOR-I), has been shown to enhance immunoregulatory profiles in liver...” PMID 31721246 ↗ Jun 202010“A large industry sponsored phase III clinical trial has been underway for several years where patients have substituted sirolimus (SRL) for calcineurin inhibitors after liver...” NCT01134952 ↗ “low-immunological-risk, CMV-positive kidney transplant recipients receiving preemptive therapy were randomized to be converted (sirolimus [SRL]) or not (control [CTR])” PMID 37046380 ↗ Jul 2023 “This study will evaluate whether conversion from cyclosporine, a calcineurin inhibitor (CI) to sirolimus (SRL) results in improved long-term renal function” NCT00452361 ↗ “conversion from cyclosporine to the mTOR inhibitor, sirolimus (SRL), results in immune tolerance” NCT02979873 ↗ “Sirolimus (SRL) has a considerable inter- and intra- individual variability in clearance.” PMID 15660173 ↗ Jan 2005 “tacrolimus (TAC) with sirolimus (SRL) was associated with worse post-transplant outcomes” PMID 28810721 ↗ Aug 2017 “de novo CNI minimization combined with sirolimus (SRL) improves graft survival” PMID 19670189 ↗ Jun 2009 “Sirolimus (SRL) has a concentration-related effect on hematopoiesis.” PMID 17565578 ↗ Jun 2007 “Mammalian target of rapamycin inhibitors (mTORi), sirolimus (SRL)” PMID 37525373 ↗ Aug 2023 “Sirolimus(SRL)-based immunosuppression” NCT01195194 ↗ |
| Known as | TD201 | “1% sirolimus cream (TD201 1%)” NCT02152007 ↗ |
| Action | Inhibit | “It inhibits T and B cell activity.” NCT00005113 ↗ |
| Modality | Small molecule | “It is a macrocyclic lactone” NCT00795886 ↗ |
| Route | Oral | “SRL is administered as an oral dose of 3 mg/m2/day.” NCT00005113 ↗ |
| Target | MTOR | “the mTOR inhibitor, sirolimus” PMID 21915260 ↗ Sep 2011 |